Evommune's EVO756 fails Phase 2b atopic dermatitis trial, shifts focus to EVO301

Evommune announced on September 8, 2026 that its Phase 2b trial of EVO756 in moderate-to-severe atopic dermatitis did not meet its main goal. The trial enrolled 121 adults with moderate-to-severe AD, ran a 12-week treatment period with follow-up through Week 14, and failed to meet the primary or secondary endpoints across all doses tested.¹ The primary endpoint was percent change in Eczema Area and Severity Index score from baseline at Week 12.

As a result, Evommune does not plan to advance EVO756 further in atopic dermatitis.¹ Chief Medical Officer Eugene Bauer said the company was disappointed by the miss, but noted that EVO756 was generally well tolerated, with a safety profile in line with earlier studies, which supports continuing to test it for migraine prevention.¹

The company's attention now turns to EVO301, a long-acting injectable IL-18BP fusion protein. CEO Luis Peña said EVO301, which recently produced positive Phase 2a proof-of-concept results, is set to begin a Phase 2b trial in mid-2027.¹ The 8-K describes EVO301 as designed to neutralize excess IL-18 activity, with features intended to improve tissue distribution, binding affinity, and specificity compared with existing approaches such as traditional monoclonal antibodies, including a smaller molecular weight and extended half-life.¹

On finances, Evommune said that under its current business plans, including the revised clinical strategy, its cash, cash equivalents, and investments are expected to fund operations into 2029.¹